Related Experiment Video
Updated: May 3, 2026

Size Exclusion Chromatography to Analyze Bacterial Outer Membrane Vesicle Heterogeneity
Published on: March 31, 2021
Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine
Chiara Tani1, Maria Stella1, Danilo Donnarumma1
1Novartis Vaccines and Diagnostics, Via Fiorentina, 1 53100 Siena, Italy.
Abstract:
Meningococcal disease is a major cause of morbidity and mortality worldwide. Its epidemiology is currently dominated by five capsular serogroups (A, B, C, W, and Y). While effective vaccines already exist for serogroups A, C, W and Y, except for under clonal outbreaks, no vaccine was available against serogroup B. Recently, a four component vaccine, Bexsero(®), designed to prevent infection caused by this serogroup, has been approved in Europe and other Countries for use in individuals from two months of age and older. The active components of this vaccine are three recombinant proteins identified by reverse vaccinology combined with detergent extracted outer membrane vesicles (DOMV) prepared from a New Zealand epidemic strain. Considering their intrinsic complexity, we performed additional characterization of DOMVs on top of the standard quality control testing carried out for batch release. We applied the Hi3 label-free LC-MS(E) methodology to qualitatively and quantitatively characterize the DOMV protein content. We first, successfully investigated the robustness and the accuracy of the methodology for the DOMV characterization and we then applied it to compare six DOMV production lots. Around 100 proteins were quantified from each preparation. When classified according to their predicted cellular localization, about 90% of the total protein amount belongs consistently to the outer membrane compartment. Using nonparametric hypothesis testing and complementary log-log linear regression, the quantifications of a subset of 21 proteins common to all lots and including approximately 90% (85-92%) of the total protein amount quantified in any DOMV lot were found consistent across lots. The relevance of these results is two-fold, showing that the Hi3 quantification methodology is robust for a broad range of proteins and indicating that the manufacturing process currently used for the production of the Bexsero(®) DOMV components is highly reproducible and consistent.
Insights
Bexsero, a new vaccine against serogroup B meningococcal disease, uses detergent extracted outer membrane vesicles (DOMVs). This study confirms the vaccine
Area of Science:
- Vaccinology
- Microbiology
- Analytical Chemistry
Background:
- Meningococcal disease poses a significant global health threat, with serogroup B being a primary concern due to the lack of a widely available vaccine.
- Bexsero(®) is a novel vaccine approved for preventing serogroup B meningococcal infections, utilizing detergent extracted outer membrane vesicles (DOMVs) from a New Zealand epidemic strain.
Purpose of the Study:
- To perform additional characterization of DOMVs used in Bexsero(®) beyond standard quality control.
- To assess the robustness and accuracy of the Hi3 label-free LC-MS(E) methodology for DOMV protein content analysis.
- To compare the consistency of DOMV protein composition across multiple production lots.
Main Methods:
- Utilized the Hi3 label-free liquid chromatography-tandem mass spectrometry (LC-MS(E)) technique.
- Analyzed the protein content of detergent extracted outer membrane vesicles (DOMVs).
- Applied nonparametric hypothesis testing and complementary log-log linear regression for quantitative analysis.
Main Results:
- Successfully validated the Hi3 LC-MS(E) methodology for DOMV characterization.
- Quantified approximately 100 proteins per DOMV preparation, with ~90% consistently identified as outer membrane proteins.
- Demonstrated high consistency in the quantification of 21 key proteins across six DOMV production lots, representing 85-92% of the total protein content.
Conclusions:
- The Hi3 quantification methodology is robust for characterizing a wide range of proteins in DOMVs.
- The manufacturing process for Bexsero(®) DOMV components exhibits high reproducibility and consistency.
- These findings support the quality and reliability of the Bexsero(®) vaccine's active components.

